Nordicus Partners Corp · OTC:NORD
Nordicus Partners — Investor Presentation (March 2025)
12 slides from Nordicus Partners's investor presentation, Mar 6, 2025
Slide 1: Advancing the Next Generation of Periodontitis Therapies
Orocidin ADVANCING THE NEXT GENERATION OF PERIODONTITIS THERAPIES Developing a treatment to patients lacking effective medical options
Slide 2: Who We Are
Orocidin Who We Are About Us Orocidin A/S is a Danish preclinical biotech company founded in 2023 by Allan Wehnert, an accomplished pharmacologist and former Senior VP at Lundbeck A/S, who serves as Orocidin’s CEO. In 2024, Orocidin became a wholly owned subsidiary of Nordicus Partners Corp (OTCQB:
Slide 3: Understanding Periodontitis
Understanding Periodontitis ° ° ° Periodontitis is a severe gum disease caused by bacterial infections Leading consequences are inflammation, gum recession, and ultimately, the destruction of the bone supporting the teeth. However, it is more than just an oral health issue—it is a serious medical co
Slide 4: Committed to improving lives around the world
Committed to improving lives around the world ° fe} O° Today, millions of periodontitis patients do not have sufficient and effective medical treatment available to them. Current treatments are inadequate and with limited efficacy as they only manage progression of the disease. This require lifelong
Slide 5: Domestic & International Partners
Orocidin Domestic & International Partners Orocidin collaborates with leading domestic and international experts across various aspects of drug development, reinforcing our commitment to creating the top medical treatment for periodontitis patients worldwide. 3 SY BOWS TRR BOP SURG
Slide 6: Orocidin's R&D Pipeline
Orocidin’s R&D Pipeline Product Disease Area Pre-Clinical Development — QR-01 Q4 2025 2"4 pivotal toxicity study expected to be completed by ultimo Q2 2025 Completion of 2"¢ 18 toxicity study toxicity study completed Positive results as 1% toxicity study shows a well tolerated product Initiate pilot
Slide 7: Disease Prevalence
Orocidin DISEASE PREVALENCE Periodontal diseases affect 20-50% of the global population — making it the 6" most prevalent health condition. ‘f i fi | Severe periodontitis affects 11% globally — ‘ i i * — Sexually transmitted infections: 16% compared to other diseases?: fi \ * Cardiovascular disease:
Slide 8: Economic Statistics
0.00 Orocidin Economic Statistics Economic Loss of Periodontal Diseases In 2018 (Billion USD)® . . . Europe Market Size - Periodontal Disease (32 countries) USA Uli 5 (Billion USD) Direct Costs 3.18 3.49 Indirect Costs: 197.09 150.57 ga sEeEE & Total Costs 200.27 154.06 _ 2022 _ 2023 _ 2024 _ 2025 _
Slide 9: Orocidin's Drug Delivery System
Orocidin OROCIDIN’S DRUG DELIVERY SYSTEM Orocidin’s breakthrough is not only the discovery and repurposing ° of QR-01 for treating periodontitis. © A key challenge in oral drug delivery is ensuring that the active ingredient remains in the mouth long enough to be effective. It is imperative that the
Slide 10: Orocidin-A Game Changer!
OROCIDIN-A GAME CHANGER! © AGame-Changing Treatment for Periodontitis: = Orocidin’s combination of QR-01 with its innovative proprietary gel formulation repr akthrough in periodontitis treatment. This drug has the potential to significantly impact the field of periodontal medicine by providing the f
Slide 11: Thank you!
Thank you! Do you have any questions? [email protected] +45 42 90 17 33 Dyrehavevej 3B G/F DK-2930 Klampenborg Denmark www.orocidin.com 11
Slide 12: List of References
List of References a ~ » - = - Nazir M. et al. (2020) Global Prevalence of Periodontal Disease and Lack of Its Surveillance, ScientificWorldJournal. 2020 May 28;2020:2146160. doi: 10.1155/2020/2146160, National Library of Medicine. https://pme.ncbi.nlm.nih.gov/articles/PMC7275199, FDI World Dental F
Nordicus Partners — Investor Presentation (March 2025) on 6ix